Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

From recurrent flank pain to systemic oxalosis: a case of primary hyperoxaluria type 1 requiring dual organ transplantation.

Annals of medicine and surgery (2012)·2026

Same author

Impact of lupus nephritis on foeto-maternal outcomes: A retrospective case-control study.

JPMA. The Journal of the Pakistan Medical Association·2026

Same author

CRISPR Cas9 mediated genome editing to induce apoptosis a new strategy to tackle cancer.

Nucleosides, nucleotides & nucleic acids·2026

Same author

Inhibitory potential of Morus alba leaf extract and its phytoconstituent against SARS-CoV-2 main protease: An integrative in silico and in vitro analysis.

Journal of molecular graphics & modelling·2026

Same author

The elimination of trachoma in Fiji: lessons for global public health.

International health·2026

Same author

A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia.

Journal of hypertension·2026

Same journal

Immunohistochemistry (IHC) Versus Genomic Profiling in Cancer: Roles in Precision Medicine.

Cureus·2026

Same journal

Pediatric Nasal Tip Reconstruction After a Donkey Bite Using an Expanded Paramedian Forehead Flap With Conchal Cartilage Grafts: A Case Report.

Cureus·2026

Same journal

Splenic Rupture: A Delayed and Rare Complication of Colonoscopy.

Cureus·2026

Same journal

Super-refractory Status Epilepticus in Febrile Infection-Related Epilepsy Syndrome Triggered by Influenza A: A Pediatric Case Report.

Cureus·2026

Same journal

Comparative Evaluation of Serum Peroxiredoxin 2 (PRDX2), Serum Peroxiredoxin 4 (PRDX4), and Plasma Methylated Septin 9 (mSEPT9) Levels Against Conventional Biomarkers for Early Detection of Colorectal Cancer: A Study Protocol.

Cureus·2026

Same journal

Inspiratory Muscle Training for Patients With Chronic Obstructive Pulmonary Disease: A Narrative Review.

Cureus·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

Semaglutide-Induced Lupus Erythematosus With Multiorgan Involvement.

Vanessa Castellanos¹, Hiwot Workneh², Ayesha Malik¹

¹Internal Medicine, Hackensack Meridian Mountainside Medical Center, Montclair, USA.

|April 1, 2024

Summary

This summary is machine-generated.

A patient developed a petechial rash and liver issues after starting semaglutide (a GLP-1 RA). Symptoms improved with steroids, suggesting a drug-induced lupus diagnosis.

Area of Science:

Hepatology
Immunology
Pharmacology

Background:

Keywords:

autoimmune hepatitis drug induced hepatitis drug-induced cutaneous vasculitis drug-induced lupus (dil)glp-1 agonist semaglutide

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Related Experiment Videos

Last Updated: Jun 7, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide are increasingly used for type 2 diabetes and weight management.
Adverse events associated with GLP-1 RAs are typically gastrointestinal, but rarer immune-mediated reactions are possible.
This case highlights a potential, albeit uncommon, adverse effect of semaglutide impacting the liver and skin.